You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,122,018


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,122,018
Title:Device and method for treatment of wounds with nitric oxide
Abstract: Topical exposure of nitric oxide gas to wounds such as chronic non-healing wounds may be beneficial in promoting healing and preparing the wound bed for further treatment and recovery. Nitric oxide gas may be used to reduce the microbial infection, manage exudates secretion by reducing inflammation, upregulate expression of endogenous collagenase to locally debride the wound, and regulate the formation of collagen. High concentration of nitric oxide ranging from 160 400 ppm may be used without inducing toxicity in the healthy cells around a wound site. Exposure to the high concentration for a first treatment period reduces the microbial burden and inflammation, and increases collagenase expression to debride necrotic tissue at the wound site. After a first treatment period, a second treatment period at a lower concentration of nitric oxide, preferably ranging from 5 20 ppm may be used to restore the balance of nitric oxide and induce collagen expression aiding in the wound closure.
Inventor(s): Stenzler; Alex (Long Beach, CA), Miller; Chris C (North Vancouver, CA)
Assignee: Sensormedics Corporation (Yorba Linda, CA) Pulmonox Technologies Corporation (Edmonton, CA)
Application Number:11/021,109
Patent Claims:1. A method to promote healing of a wound of a subject, the method comprising the steps of: providing a flow-controlled source of nitric oxide gas; exposing the wound to a high concentration of exogenous nitric oxide gas for a treatment period without inducing toxicity to the subject or the healthy cells surrounding the wound; and exposing the wound to a decreased concentration of exogenous nitric oxide gas for a second treatment period sufficient to increase the expression of collagen MRNA.

2. The method of claim 1, further comprising the step of monitoring the concentrations of nitric oxide gas.

3. The method of claim 2, wherein the decreased concentration of nitric oxide gas is about 5 ppm.

4. The method of claim 2, wherein the treatment period is about 7 hours and the second treatment period is at least about 7 hours.

5. The method of claim 1, further comprising the step of monitoring of the levels of collagenase produced by cells surrounding the wound.

6. The method of claim 1, further comprising the step of monitoring the levels of collagen produced by cells surrounding the wound.

7. The method of claim 1, further comprising the step of removing of excess exudate from the wound.

8. The method of claim 1, wherein the high concentration of nitric oxide gas is greater than about 200 ppm.

9. The method of claim 8, wherein the high concentration of nitric oxide gas is about 200 ppm to 400 ppm.

10. The method of claim 1, wherein the treatment period is at least about 7 hours.

11. The method of claim 10, wherein the exposure to the high concentration of nitric oxide gas in the first treatment period is continuous.

12. A method of reducing scarring in a healing process of a wound, the method comprising the steps of: providing a flow-controlled source of nitric oxide gas; exposing the wound to a high concentration of exogenous nitric oxide gas for a treatment period without inducing toxicity to the subject or to healthy cells surrounding the wound, exposing the wound to a decreased concentration of exogenous nitric oxide gas for a second treatment period sufficient to increase the expression of collagen mRNA; and exposing the wound to a third concentration of exogenous nitric oxide gas for a third treatment period, wherein the third concentration is between the high concentration and the decreased concentration.

13. The method of claim 12, wherein the high concentration ranges from about 200 ppm to 400 ppm, the decreased concentration ranges from about 5 ppm to 20 ppm, and the third concentration ranges from about 20 ppm to 200 ppm.

14. The method of claim 12 wherein the first treatment period is at least seven hours in a day, the second treatment period ranges from 5 12 hours a day, and the third treatment period ranges from about 5 12 hours a day.

15. The method of claim 14 wherein the first treatment period, the second treatment period, and the third treatment period are repeated for multiple days.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.